Inovio Pharmaceuticals, Inc.

NasdaqCM:INO 株式レポート

時価総額：US$202.4m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Inovio Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Inovio Pharmaceuticals'の CEO はJacqueline Sheaで、 May2022年に任命され、 の在任期間は 2.08年です。 の年間総報酬は$ 2.44Mで、 30.8%給与と69.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.13%を直接所有しており、その価値は$ 300.81K 。経営陣と取締役会の平均在任期間はそれぞれ3.7年と5.6年です。

主要情報

Jacqueline Shea

最高経営責任者

US$2.4m

報酬総額

CEO給与比率30.8%
CEO在任期間2.1yrs
CEOの所有権0.1%
経営陣の平均在職期間3.7yrs
取締役会の平均在任期間5.6yrs

経営陣の近況

Recent updates

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15
Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23
Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio: After All These Years

Jul 19

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Apr 15

Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Mar 21
Inovio Pharmaceuticals (NASDAQ:INO) Has Debt But No Earnings; Should You Worry?

Inovio Undervalued On Potential 2022 Catalyst

Jan 26

Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Dec 31
Calculating The Intrinsic Value Of Inovio Pharmaceuticals, Inc. (NASDAQ:INO)

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

Nov 18

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Sep 24
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio: Simply Cannot Be Ignored

Sep 03

Inovio Has 4 Sources Of Potential Value

Jun 23

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Jun 11
Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Inovio stock trades higher defying insider sale

Jun 07

CEO報酬分析

Inovio Pharmaceuticals の収益と比較して、Jacqueline Shea の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$125m

Dec 31 2023US$2mUS$751k

-US$135m

Sep 30 2023n/an/a

-US$165m

Jun 30 2023n/an/a

-US$168m

Mar 31 2023n/an/a

-US$241m

Dec 31 2022US$4mUS$730k

-US$280m

Sep 30 2022n/an/a

-US$332m

Jun 30 2022n/an/a

-US$355m

Mar 31 2022n/an/a

-US$328m

Dec 31 2021US$2mUS$468k

-US$304m

Sep 30 2021n/an/a

-US$221m

Jun 30 2021n/an/a

-US$142m

Mar 31 2021n/an/a

-US$188m

Dec 31 2020US$2mUS$431k

-US$166m

Sep 30 2020n/an/a

-US$180m

Jun 30 2020n/an/a

-US$222m

Mar 31 2020n/an/a

-US$123m

Dec 31 2019US$1mUS$335k

-US$119m

報酬と市場: Jacquelineの 総報酬 ($USD 2.44M ) は、 US市場 ($USD 1.62M ) の同規模の企業の平均を上回っています。

報酬と収益: Jacquelineの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Jacqueline Shea (58 yo)

2.1yrs

在職期間

US$2,438,908

報酬

Dr. Jacqueline E. Shea, Ph D., serves as Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief Opera...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Jacqueline Shea
CEO, President & Director2.1yrsUS$2.44m0.13%
$ 262.8k
Peter Kies
Chief Financial Officer22yrsUS$1.16m0.095%
$ 193.2k
Laurent Humeau
Chief Scientific Officer5.3yrsUS$1.14m0.094%
$ 190.1k
Thomas Hong
Manager of Investor Relationsno dataデータなしデータなし
Robert Crotty
General Counsel & Chief Compliance Officer2.6yrsデータなしデータなし
E. Brandreth
Senior Vice President of Quality Assuranceno dataデータなしデータなし
Jeffrey Skolnik
Senior Vice President of Clinical Development3.7yrsデータなしデータなし
Robert Juba
Senior Vice President of Biological Manufacturing & Clinical Supply Management3.7yrsデータなしデータなし
Stephen Kemmerrer
Senior Vice President of Engineering Developmentno dataデータなしデータなし
Shawn Bridy
Senior Vice President of Business Development3.4yrsデータなしデータなし
Mark Twyman
Chief Commercial Officer3.7yrsデータなしデータなし
David Liebowitz
Senior Vice President of Early-Stage Clinical Developmentless than a yearデータなしデータなし

3.7yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: INOの経営陣は 経験豊富 であると考えられます ( 3.7年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Jacqueline Shea
CEO, President & Director2.1yrsUS$2.44m0.13%
$ 262.8k
Wendy Yarno
Independent Director6.5yrsUS$123.69k0.032%
$ 65.2k
Lota Zoth
Independent Director5.4yrsUS$118.69k0.025%
$ 51.2k
Jay Shepard
Independent Director4.4yrsUS$119.31k0.027%
$ 55.0k
Simon Benito
Independent Chairman of Board of Directors20.5yrsUS$151.19k0.039%
$ 78.3k
David B. Weiner
Chairman of the Scientific Advisory Board & Director24.4yrsUS$201.79k0.32%
$ 644.4k
Stanley Plotkin
Member of Scientific Advisory Board15yrsデータなしデータなし
Ann Miller
Independent Director5.3yrsUS$126.94k0.030%
$ 60.2k
Anthony Ford-Hutchinson
Member of Scientific Advisory Board12.3yrsデータなしデータなし
Roger Dansey
Independent Director3.1yrsUS$108.69k0.026%
$ 52.7k
Rafi Ahmed
Member of Scientific Advisory Board5.6yrsデータなしデータなし

5.6yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: INOの 取締役会 は 経験豊富 であると考えられます ( 5.6年の平均在任期間)。